Pacira BioSciences Plans $30M Q2 R&D Ramp and H2 SG&A Cuts
Pacira BioSciences expects Q2 R&D spend to hit the low $30 million range for ASCEND Part B before dropping to Q1 levels in Q3–Q4 and will trim SG&A below current levels in H2. Partnerships with Johnson & Johnson MedTech and LG Chem bolster growth, though No Pain Act expiry in 2027 risks reimbursement.
1. Q2 R&D Spending Guidance
Pacira BioSciences forecasts R&D expenses rising to the low $30 million range in Q2 driven by initiation of ASCEND Part B and EXPAREL development efforts, then tapering back to Q1 levels in Q3 and Q4.
2. SG&A Cost Reduction Plan
After five quarters of elevated SG&A spending, management expects to reduce these expenses slightly below current levels in the second half of the year, reflecting efficiencies post-proxy season.
3. Partnerships Driving Growth
Strategic alliances with Johnson & Johnson MedTech and LG Chem are key components of the 5×30 strategy, aimed at expanding ex-US commercial reach and sustaining revenue growth through and beyond 2030.
4. Reimbursement and Regulatory Risks
The No Pain Act is set to expire in 2027, creating uncertainty around future reimbursement policies and potential impacts on EXPAREL usage and overall revenue.